AI
Isomorphic Labs raises $5B to advance AI drug discovery platform
Alphabet's pharmaceutical AI subsidiary secures massive funding round led by Greenoaks and Sequoia to accelerate clinical trials and expand bioengineering capabilities.
Key takeaways
- Isomorphic Labs closed a $5 billion funding round led by Greenoaks and Sequoia Capital, with participation from parent company Alphabet.
- The company's IsoDDE platform uses AI to identify protein binding pockets and design drug compounds without requiring traditional crystallization methods.
- Multiple pharmaceutical companies are already using the platform in active drug discovery programs.
- Isomorphic plans to use the capital to build bioengineering infrastructure and advance its first therapeutic programs toward clinical trials.
- The platform eliminates expensive free energy perturbation steps and produces results faster than conventional drug development methods.
Alphabet subsidiary secures landmark funding
Isomorphic Labs has closed a $5 billion investment round led by Greenoaks and Sequoia Capital, with participation from parent company Alphabet through its GV and CapitalG venture arms, according to SiliconANGLE. The substantial capital injection will fund the expansion of Isomorphic's AI-driven drug discovery platform, which multiple pharmaceutical companies are already using in active programs.
The Alphabet subsidiary develops the Isomorphic Labs Drug Design Engine (IsoDDE), a software platform that applies artificial intelligence to accelerate core tasks in pharmaceutical development. The technology addresses bottlenecks that have traditionally made drug discovery a time-intensive and expensive process.
How the platform streamlines drug development
Drug development typically requires researchers to identify vulnerable proteins within pathogens and then engineer compounds that can neutralize them. This process begins with mapping protein structures to locate binding pockets—surface recesses where drug molecules can attach. The challenge is compounded by the fact that proteins constantly change shape as they interact with other molecules and respond to environmental conditions.
IsoDDE uses AI to identify these binding pockets more rapidly than conventional methods. When suitable pockets don't exist naturally, the platform helps researchers design compounds that induce target proteins to form them.
The next phase traditionally involves free energy perturbation (FEP) algorithms to determine how drug molecules can attach to binding sites. FEP methods are computationally expensive and typically require detailed three-dimensional protein models created through a labor-intensive process: freezing proteins in crystals and scanning them with specialized X-ray equipment.
Isomorphic's platform eliminates the need for this crystallization step entirely. The company claims IsoDDE produces higher-quality results than standard FEP approaches while reducing both time and cost.
Why it matters
The $5 billion valuation signals investor confidence that AI can fundamentally reshape pharmaceutical R&D economics. Traditional drug development can take over a decade and cost billions per approved therapy. If Isomorphic's platform delivers on its promise to compress timelines and reduce the need for expensive experimental infrastructure, it could accelerate the path from target identification to clinical trials—potentially bringing treatments to patients years faster while lowering development costs for pharmaceutical partners.
Expansion plans and clinical goals
"Our drug design engine is generating molecules with unprecedented precision and speed," said Demis Hassabis, Isomorphic's chief executive, in the announcement. "This round enables us to accelerate our progress: building foundational biology models, deepening our systemic disease understanding, and driving our first therapeutic programs towards clinical trials."
The company plans to invest the capital in new bioengineering infrastructure and expanding its pharmaceutical partnership network. Moving internal therapeutic programs toward clinical trials represents a significant milestone, as it would demonstrate the platform's ability to produce drug candidates that meet regulatory standards for human testing.
Details of the funding round were first reported by SiliconANGLE.